Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.

The three-dimensional structures of aldose reductase and aldehyde reductase, members of the aldo-keto reductase superfamily, are composed of similar alpha/beta TIM-barrels. However, examination of the structures reveals that the inhibitor-binding site of aldose reductase differs from that of aldehyde reductase due to the participation of non-conserved residues in its formation. This information will be useful in the design of inhibitors to prevent or delay diabetic retinopathy. A review of the structures of the inhibitor-binding sites is presented.

[1]  P. Kador,et al.  Inhibition of aldehyde reductase by aldose reductase inhibitors. , 1990, Biochemical pharmacology.

[2]  Sookja K. Chung,et al.  Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Ronald J. Moore,et al.  Characterization of the 3α-hydroxysteroid dehydrogenase of dog prostate , 1977 .

[4]  O. El-Kabbani,et al.  Studies on the inhibitor‐binding site of porcine aldehyde reductase: Crystal structure of the holoenzyme‐inhibitor ternary complex , 1997, Proteins.

[5]  A. Bhatnagar,et al.  Bovine lens aldose reductase. pH-dependence of steady-state kinetic parameters and nucleotide binding. , 1993, The Journal of biological chemistry.

[6]  F. Quiocho,et al.  Probing the active site of human aldose reductase. Site-directed mutagenesis of Asp-43, Tyr-48, Lys-77, and His-110. , 1993, The Journal of biological chemistry.

[7]  K. Bohren,et al.  The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. , 1996, Biochemistry.

[8]  F A Quiocho,et al.  An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. , 1992, Science.

[9]  B. Wermuth.  Aldo-keto reductases. , 1985, Progress in clinical and biological research.

[10]  B. Wermuth,et al.  Immunohistochemical localisation of aldehyde and aldose reductase in human tissues. , 1985, Progress in clinical and biological research.

[11]  S. Old,et al.  Residues affecting the catalysis and inhibition of rat lens aldose reductase. , 1995, Biochimica et biophysica acta.

[12]  M. Pfeifer,et al.  Aldose Reductase Inhibitors: The End of an Era or the Need for Different Trial Designs? , 1997, Diabetes.

[13]  K. Moore,et al.  Structures of human and porcine aldehyde reductase: an enzyme implicated in diabetic complications. , 1994, Acta crystallographica. Section D, Biological crystallography.

[14]  K. Bohren,et al.  Mechanism of human aldehyde reductase: characterization of the active site pocket. , 1995, Biochemistry.

[15]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[16]  T. Kern,et al.  Retinopathy in galactosemic dogs continues to progress after cessation of galactosemia. , 1995, Archives of ophthalmology.

[17]  M. Foppiano,et al.  Worldwide pharmacovigilance systems and tolrestat withdrawal , 1997, The Lancet.

[18]  F A Quiocho,et al.  Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T. Flynn,et al.  Studies on pig muscle aldose reductase. Kinetic mechanism and evidence for a slow conformational change upon coenzyme binding. , 1992, The Journal of biological chemistry.

[20]  G. Petsko,et al.  Tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction reaction of human aldose reductase: enzyme kinetics and crystal structure of the Y48H mutant enzyme. , 1994, Biochemistry.

[21]  M. Lewis,et al.  Three-dimensional structure of rat liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase: a member of the aldo-keto reductase superfamily. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Flynn,et al.  A nomenclature system for the aldo-keto reductase superfamily. , 1997, Advances in experimental medicine and biology.

[23]  O. El-Kabbani,et al.  Crystal structure of porcine aldehyde reductase at 2.0 angstrom resolution: Modeling an inhibitor in the active site of the enzyme. , 1998 .

[24]  A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. , 1990, Archives of ophthalmology.

[25]  C. Nishimura,et al.  The involvement of aldose reductase in diabetic complications. , 1988, Diabetes/metabolism reviews.

[26]  J. Pawlowski,et al.  Overexpression and mutagenesis of the cDNA for rat liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase. Role of cysteines and tyrosines in catalysis. , 1994, The Journal of biological chemistry.

[27]  J. Nyengaard,et al.  Hyperglycemic Pseudohypoxia and Diabetic Complications , 1993, Diabetes.

[28]  L. DeLucas,et al.  Structure of porcine aldehyde reductase holoenzyme , 1995, Nature Structural Biology.

[29]  J. Wilson,et al.  Characterization of the 3alpha-hydroxysteroid dehydrogenase of dog prostate. , 1977, Journal of steroid biochemistry.

[30]  Y. Urade,et al.  Enzymatic conversion of prostaglandin H2 to prostaglandin F2 alpha by aldehyde reductase from human liver: comparison to the prostaglandin F synthetase from bovine lung. , 1989, The Journal of biological chemistry.

[31]  W. Zimmer,et al.  Molecular cloning of testicular 20 alpha-hydroxysteroid dehydrogenase: identity with aldose reductase. , 1993, Biochemistry.

[32]  F. G. Prendergast,et al.  Mechanism of aldose reductase inhibition: binding of NADP+/NADPH and alrestatin-like inhibitors. , 1994, Biochemistry.

[33]  F. Quiocho,et al.  1.7 A structure of FR-1, a fibroblast growth factor-induced member of the aldo-keto reductase family, complexed with coenzyme and inhibitor. , 1995, Biochemistry.

[34]  T. Flynn,et al.  Studies on human aldose reductase. Probing the role of arginine 268 by site-directed mutagenesis. , 1995, The Journal of biological chemistry.

[35]  The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. , 1995, Archives of ophthalmology.

[36]  H. Krans.  Recent clinical experience with aldose reductase inhibitors. , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[37]  T. Flynn,et al.  Kinetics and mechanism of action of aldehyde reductase from pig kidney. , 1979, Biochemical Society transactions.